KRAS mutations lead to an abnormal function of these effector molecules, which results in uncontrolled cell proliferation, resulting in cancers such as lung adenocarcinoma and pancreatic ductal adenocarcinoma. Here, KRAS is linked to pancreatic ductal adenocarcinoma.